439 related articles for article (PubMed ID: 16243804)
1. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
[TBL] [Abstract][Full Text] [Related]
2. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
Rajkumar T; Samson M; Rama R; Sridevi V; Mahji U; Swaminathan R; Nancy NK
Breast Cancer Res Treat; 2008 Nov; 112(1):81-7. PubMed ID: 18058229
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.
Malisic E; Jankovic R; Slavkovic D; Milovic-Kovacevic M; Radulovic S
J BUON; 2010; 15(1):101-6. PubMed ID: 20414935
[TBL] [Abstract][Full Text] [Related]
4. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.
Noma C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Cancer Lett; 2004 Jul; 210(2):197-203. PubMed ID: 15183535
[TBL] [Abstract][Full Text] [Related]
5. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
[TBL] [Abstract][Full Text] [Related]
6. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
Hu Y; McDermott MP; Ahrendt SA
Clin Cancer Res; 2005 Apr; 11(7):2502-9. PubMed ID: 15814626
[TBL] [Abstract][Full Text] [Related]
7. P53 codon 72 polymorphism in breast cancer.
Buyru N; Tigli H; Dalay N
Oncol Rep; 2003; 10(3):711-4. PubMed ID: 12684648
[TBL] [Abstract][Full Text] [Related]
8. p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers.
Ji X; Neumann AS; Sturgis EM; Adler-Storthz K; Dahlstrom KR; Schiller JT; Wei Q; Li G
Carcinogenesis; 2008 Apr; 29(4):875-9. PubMed ID: 18258602
[TBL] [Abstract][Full Text] [Related]
9. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer.
Lee JM; Shun CT; Wu MT; Chen YY; Yang SY; Hung HI; Chen JS; Hsu HH; Huang PM; Kuo SW; Lee YC
Mutat Res; 2006 Feb; 594(1-2):181-8. PubMed ID: 16318864
[TBL] [Abstract][Full Text] [Related]
10. Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma.
Zhang ZW; Newcomb P; Hollowood A; Feakins R; Moorghen M; Storey A; Farthing MJ; Alderson D; Holly J
Clin Cancer Res; 2003 Jun; 9(6):2151-6. PubMed ID: 12796380
[TBL] [Abstract][Full Text] [Related]
11. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk.
Damin AP; Frazzon AP; Damin DC; Roehe A; Hermes V; Zettler C; Alexandre CO
Cancer Detect Prev; 2006; 30(6):523-9. PubMed ID: 17113725
[TBL] [Abstract][Full Text] [Related]
12. The p53 codon 72 polymorphism and lung cancer risk.
Fan R; Wu MT; Miller D; Wain JC; Kelsey KT; Wiencke JK; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1037-42. PubMed ID: 11045785
[TBL] [Abstract][Full Text] [Related]
13. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
14. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
15. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
16. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia.
Hadhri-Guiga B; Toumi N; Khabir A; Sellami-Boudawara T; Ghorbel A; Daoud J; Frikha M; Gargouri A; Mokdad-Gargouri R
Cancer Genet Cytogenet; 2007 Oct; 178(2):89-93. PubMed ID: 17954263
[TBL] [Abstract][Full Text] [Related]
17. Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population.
Franeková M; Zúbor P; Stanclová A; Dussan CA; Bohusová T; Galo S; Dobrota D; Kajo K; Péc M; Racay P
Neoplasma; 2007; 54(2):155-61. PubMed ID: 17319790
[TBL] [Abstract][Full Text] [Related]
18. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
19. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
20. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients.
Høgdall EV; Høgdall CK; Christensen L; Glud E; Blaakaer J; Bock JE; Vuust J; Nørgaard-Pedersen B; Kjaer SK
Anticancer Res; 2002; 22(3):1859-64. PubMed ID: 12168882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
